| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212322A2 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/12/2002 | EP1212303A2 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 06/12/2002 | EP1212302A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 06/12/2002 | EP1212120A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212086A1 Immunological tolerance-induction agent |
| 06/12/2002 | EP1212052A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 06/12/2002 | EP1023263B1 Novel vitamin d analogues |
| 06/12/2002 | EP0881901B1 New associations of active principles containing clopidogrel and an antithrombotic agent |
| 06/12/2002 | EP0802800B1 Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| 06/12/2002 | CN1353717A Tetracyclic progesterone receptor modulator compounds and methods |
| 06/12/2002 | CN1353699A Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 06/11/2002 | US6403764 Variant wherein amino acid residue at position 16 of native-sequence human igf-1 is replaced with glycine or serine, or amino acid residue at position 25 or 49 or residues at 3 and 49 are replaced with alanine, glycine, or serine |
| 06/11/2002 | US6403638 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| 06/11/2002 | US6403615 Treats osteoporosis, hyperlipidemia, and cardiovascular disorders associated with menopause; side effect reduction compared to estrogen-replacement therapy |
| 06/11/2002 | US6403614 Such as 2-(4-(methylthiomethoxy)phenyl)-3-(4-(2-piperidin-1-yl)ethoxy) benzoyl)-6-methylthiomethoxybenzo(b)thiophene;inhibition of osteoporosis, hyperlipedemia, cancer, postmenopausal syndrome, |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | CA2276614C Analogs of parathyroid hormone |
| 06/11/2002 | CA2262692C Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| 06/06/2002 | WO2002044142A2 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
| 06/06/2002 | WO2002044120A1 Compounds active at the glucocorticoid receptor iii |
| 06/06/2002 | WO2002043767A1 Improved oral delivery of peptides using enzyme-cleavable membrane translocators |
| 06/06/2002 | WO2002043766A1 Medicinal compositions and process for producing the same |
| 06/06/2002 | WO2002043750A2 Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
| 06/06/2002 | WO2002043728A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/06/2002 | WO2002043721A1 Treatment of statin side effects |
| 06/06/2002 | WO2002043695A2 Stable, aerosolizable suspensions of proteins (e.g. insulin, dnase) in ethanol |
| 06/06/2002 | WO2002043648A2 Compounds active at the glucocorticoid receptor ii |
| 06/06/2002 | WO2002043578A2 Determination of risk and treatment of complications of prematurity |
| 06/06/2002 | WO2002003914A3 Improved thyroid hormone formulations |
| 06/06/2002 | WO2001094293A3 Benzamide ligands for the thyroid receptor |
| 06/06/2002 | WO2001090334A3 Drug metabolizing enzymes |
| 06/06/2002 | WO2001087849A3 Modulators of tnf- alpha signaling |
| 06/06/2002 | WO2001079442A3 Albumin fusion proteins |
| 06/06/2002 | WO2001002012A8 Remedies for drug-resistant hypercalcemia |
| 06/06/2002 | US20020068765 8,9-dihydro-7H-benzocycloheptene derivatives are useful for phophylaxis and therapy of osteoporosis(have selective estrogenic activity on bones) |
| 06/06/2002 | US20020068746 Pyrrolo[2,3-d]pyrimidine compounds |
| 06/06/2002 | US20020068736 Biphenyl compounds and their use as oestrogenic agents |
| 06/06/2002 | US20020068735 Progesterone receptor antagonist; inhibiting breast, uterine, ovarian, endometrial, or prostate cancer |
| 06/06/2002 | US20020068723 Altering the conformational equilibrium of the A- ring to favor a chair conformation that presents the 1 alpha-hydroxyl in the axial orientation. |
| 06/06/2002 | US20020068319 32 human secreted proteins |
| 06/06/2002 | CA2457925A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/06/2002 | CA2430311A1 Compounds active at the glucocorticoid receptor ii |
| 06/06/2002 | CA2430139A1 Stable, aerosolizable suspensions of proteins in ethanol |
| 06/06/2002 | CA2430137A1 Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
| 06/06/2002 | CA2429615A1 Determination of risk and treatment of complications of prematurity |
| 06/05/2002 | EP1211319A2 Gene transfer into pancreatic and biliary epithelial cells |
| 06/05/2002 | EP1211313A2 Modulation of PDE11A activity |
| 06/05/2002 | EP1210951A2 Combination for treating andropause containing estrogen agonists/antagonists and testosterone |
| 06/05/2002 | EP1210937A2 Device for topical treatment of acne and its method of manufacture |
| 06/05/2002 | EP1210455A1 Novel glycosyl sulfotransferases gst-4 alpha, gst-4 beta, and gst-6 |
| 06/05/2002 | EP1210341A1 Compositions and therapeutic methods involving isoflavones and analogues thereof |
| 06/05/2002 | EP1210339A1 Benzoic acid derivatives for the treatment of diabetes mellitus |
| 06/05/2002 | EP1210121A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 06/05/2002 | EP1210063A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 06/05/2002 | EP1117420B1 Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues |
| 06/05/2002 | EP1021191B1 Tightening and/or reducing the size of body parts containing fat cells |
| 06/05/2002 | EP0923539B1 Compounds with growth hormone releasing properties |
| 06/05/2002 | EP0858338B1 Use of levo-enantiomers of medetomidine derivatives |
| 06/05/2002 | EP0684825B1 Kit for preventing or inhibiting fertilization |
| 06/05/2002 | CN1352686A Cytokine receptor chain |
| 06/05/2002 | CN1352545A 吲哚衍生物 Indole derivatives |
| 06/05/2002 | CN1085980C Meta-guanidine, urea, thiourea or azacyclic amino benzoic and derivatives as integrin antagaonists |
| 06/04/2002 | US6399797 Vitamin D analogues |
| 06/04/2002 | US6399778 Crystalline solvate |
| 06/04/2002 | US6399745 Use of leptin antagonists for treating insulin resistance in type II diabetes |
| 06/04/2002 | US6399595 Steroid sulfatase inhibitors and methods for making and using the same |
| 06/04/2002 | US6399594 With water insoluble starch carrier; allows dry storage and lower doses of active ingredient |
| 06/04/2002 | US6399593 Contraceptives |
| 06/04/2002 | US6399101 Levothyroxine sodium and silicified microcrystalline cellulose; tablets; light, heat, and humidity stable |
| 06/04/2002 | CA2302396C Allosteric adenosine receptor modulators |
| 05/30/2002 | WO2002042332A2 Truncated cd200 |
| 05/30/2002 | WO2002042302A1 Novel sulfonamide-substituted pyrazolopyridine derivatives |
| 05/30/2002 | WO2002042278A2 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | WO2002041835A2 Estrogen receptor modulators |
| 05/30/2002 | WO2002022599A3 Chemokine receptor binding heterocyclic compounds |
| 05/30/2002 | WO2002020526A3 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 05/30/2002 | WO2001095928A3 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 05/30/2002 | WO2001091724A3 Transdermal delivery of lasofoxifene |
| 05/30/2002 | WO2001078683A3 Sustained release formulations comprising growth hormone |
| 05/30/2002 | WO2001077055A3 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 05/30/2002 | WO2001068888A3 Production of chimeric capsid vectors |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | WO2000066581A8 Cyanopyrroles as progesterone receptor agonists |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065277 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 05/30/2002 | US20020065257 17beta-amino and hydroxylamino-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 05/30/2002 | US20020065256 Antiinflammatory and antiallergic glucocorticosteroid, sterile glucocorticosteroids |
| 05/30/2002 | US20020064843 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/30/2002 | CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | CA2429579A1 Truncated cd200 |
| 05/30/2002 | CA2429313A1 Novel sulfonamide-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2363935A1 Therapy for andropause using estrogen agonists/antagonists and testosterone |
| 05/29/2002 | EP1208201A2 Compositions and methods for the treatment of immune related diseases |
| 05/29/2002 | EP1208113A2 17beta-acyl-alpha-propynyl-11beta-(cyclic amino)aryl steroids and their derivatives having antagonist hormonal properties |
| 05/29/2002 | EP1208104A2 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 05/29/2002 | EP1207884A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 05/29/2002 | EP1207881A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |